AFM-22

N/A

Report date: 2025/01/15 20:00:32

Base Information

Drug NameAFM-22

Drug Alias NameAFM-22 (Affimed)anti-CD16A activator/anti-EGFRvIII bispecific NK-cell engager AFM-22

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionEpidermal growth factor receptor erbB1 modulatorsLow affinity immunoglobulin gamma Fc region receptor III-A agonists

TargetsEpidermal growth factor receptor erbB1Low affinity immunoglobulin gamma Fc region receptor III-A

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAffimed Nv

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesAffimed Nv

Active IndicationsN/A

Inactive IndicationsNeoplasms

ATC CodeN/A